Abstract
Abstract
Background
Medical device certification has undergone significant changes in recent years. However, exploration of stakeholder experiences remains relatively limited, particularly in the context of software as a medical device. This study sought to explore stakeholder experiences of medical device certification across both the UK and EU.
Methods
Semi-structured interviews (n = 22) analysed using inductive-thematic analysis, synthesised using activity theory.
Results
Innovators, consultants and notified bodies share more similarities than differences when discussing barriers and enablers to achieving medical device certification. Systemic tensions between existing rules, tools, community understanding and division of labour currently undermine the intended aim of certification processes. Existing rules are considered complex, with small and medium-sized enterprises considered disproportionality affected, resulting in several unintended outcomes including the perceived ‘killing’ of innovation. Existing certification processes are described as unfit for purpose, unethical and unsustainable.
Conclusion
Stakeholder experiences suggest that the intention of establishing a robust and sustainable regulatory framework capable of ensuring a high level of safety whilst also supporting innovation is not yet being realised. Failure to enact desired changes may further jeopardise future innovations, outcomes and care quality.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference29 articles.
1. Hwang J, Christensen CM. Disruptive innovation in health care delivery: a framework for business-model innovation. Health Aff. 2008;27(5):1329–35.
2. Murray E, Hekler EB, Andersson G, Collins LM, Doherty A, Hollis C, et al. Evaluating digital health interventions: key questions and approaches. Amsterdam: Elsevier; 2016. p. 843–51.
3. Safavi K, Mathews SC, Bates DW, Dorsey ER, Cohen AB. Top-funded digital health companies and their impact on high-burden, high-cost conditions. Health Aff. 2019;38(1):115–23.
4. Paglialonga A, Lugo A, Santoro E. An overview on the emerging area of identification, characterization, and assessment of health apps. J Biomed Inform. 2018;83:97–102.
5. Jake-Schoffman DE, Silfee VJ, Waring ME, Boudreaux ED, Sadasivam RS, Mullen SP, et al. Methods for evaluating the content, usability, and efficacy of commercial mobile health apps. JMIR Mhealth Uhealth. 2017;5(12):e8758.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献